# Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

> **NCT06121271** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University College, London** · enrollment: 110 (estimated)

## Conditions studied

- Bronchial and Thymic Neuroendocrine Tumour
- Paraganglioma/ Phaeochromocytoma
- Medullary Thyroid Carcinoma
- Those Requiring Repeat Peptide Receptor Radionuclide Therapy

## Interventions

- **DRUG:** Lu-177 DOTATATE (Lutathera®)

## Key facts

- **NCT ID:** NCT06121271
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2027-11-06
- **Final completion:** 2027-11-06
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121271, "Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06121271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*